Idhifa, enasidenib
Named-patient access overview. Idhifa is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
This page is informational, not medical advice.
About Idhifa
Idhifa (enasidenib) is an oral, once-daily targeted therapy manufactured by Bristol-Myers Squibb following its acquisition of Celgene. It is a small-molecule inhibitor of mutant isocitrate dehydrogenase 2 (IDH2) and is indicated for adults with relapsed or refractory acute myeloid leukemia who carry a confirmed IDH2 mutation. Idhifa works by inhibiting the mutant IDH2 enzyme, reducing levels of the oncometabolite 2-hydroxyglutarate, and allowing leukemic cells to resume more normal differentiation.
Idhifa is supplied as 50 mg and 100 mg tablets. It is taken once daily by mouth, with or without food, and is generally continued until disease progression or unacceptable toxicity. Because Idhifa is an oral oncology agent at room-temperature storage, the cold-chain layer that complicates many specialty medicines is not required. It does, however, require careful supply continuity, since interruption of therapy can let leukemic burden rebuild.
For international patients whose home-country formulary does not include Idhifa, or where the IDH2 mutation-positive subset is too small to support local stocking, a named-patient pathway from the United States is often the most practical route.
Who Idhifa is for
Idhifa is generally considered for adults with acute myeloid leukemia that has relapsed after, or is refractory to, prior therapy, and whose tumor carries a documented IDH2 mutation on a validated molecular assay. The treating hematologist confirms the mutation status, weighs prior therapy, performance status, and other factors, and decides whether to initiate Idhifa. Differentiation syndrome is a serious potential adverse event, and the prescribing physician should be prepared to monitor and manage it.
How Reserve Meds coordinates Idhifa
- Patient or treating hematologist submits a named-patient request through Reserve Meds intake.
- Our clinical team verifies appropriateness of Idhifa for the patient, including IDH2 mutation confirmation and destination country.
- The treating physician issues a prescription and a brief clinical justification.
- Country-specific named-patient program or personal-import documentation is prepared.
- Idhifa is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician, hospital pharmacy, or approved address, with quantity sized to the prescribed dosing interval.
Pricing and what shapes it
Idhifa's landed price for international patients is shaped by the wholesale acquisition cost in the United States, destination-country import duties and value-added tax, logistics fees, and the Reserve Meds coordination fee. Because Idhifa is dispensed in defined tablet quantities rather than a single dose, the cost scales with the prescribed daily dose and the cycle length. Once intake is complete and destination confirmed, our coordinator issues a firm written quote covering the full landed cost before any wire is requested.
Timing expectations
From a complete intake, indicative timing for Idhifa to reach a patient in our priority markets ranges from approximately two to five weeks. The dominant variables are destination-country regulatory processing, completeness of the physician package, and customs clearance. Because Idhifa is an oral tablet at ambient temperature, transit risk is lower than for refrigerated biologics. Reserve Meds assigns each case a single named coordinator who maintains continuity from intake through delivery and refill.
Access by country
Reserve Meds publishes a detailed country deep-dive for Idhifa in every market we coordinate. Each page below covers the destination-country regulatory pathway, real costs in local currency and USD, indicative timelines, physician-credential requirements, and cold-chain handling. Tap any country to read the full deep-dive.
Storage and handling, in plain language
Idhifa tablets are stable at room temperature in the original blister and bottle packaging. They should be kept dry, away from direct sunlight, and out of reach of children. There is no cold-chain requirement, which simplifies international transit. Reserve Meds packages each shipment with tamper-evident seals and documentation that matches the wholesaler's serial records, so the receiving physician can verify provenance on arrival.
Documentation the physician will be asked to provide
The typical package includes a current prescription, a brief clinical justification letter, a copy of the physician's license, the laboratory report confirming the IDH2 mutation, and the destination-country named-patient or personal-import form where applicable. Reserve Meds prepares the country-specific paperwork; the physician supplies the clinical pieces. We aim to keep the physician's workload to under thirty minutes per case.
Privacy and data handling
Patient information collected through Reserve Meds intake is handled under HIPAA standards in the United States and the privacy regimes that apply in the destination country, including UAE PDPL, KSA PDPL, India DPDPA, and the EU GDPR where relevant. We share only the minimum necessary information with the prescribing physician, the wholesaler, the carrier, and any regulator who requires submission.
Start a request for Idhifa
Submit a 60-second intake. Our clinical team will reach out as our first cohort opens with case-specific feasibility, timeline, and a formal quote.
Reserved for you.